Pirtobrutinib for B-Cell Lymphoma Resistant to Prior Therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests pirtobrutinib, a new drug similar to ones you may have already tried, in patients whose B-cell lymphoma (a blood cancer) stopped responding to or caused side effects from prior BTK inhibitor treatments. The goal is to see if this different drug works better for people in your situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of mature B-cell lymphoma (such as CLL, MCL, FL, or WM) that got worse or caused intolerance after at least one prior BTK inhibitor drug
- Good enough overall health (able to do light activity; ECOG score 0–2)
- Adequate liver and kidney function (specific blood test requirements)
- Willing and able to complete all study visits and procedures
- No severe heart disease, active infections, or HIV/hepatitis B or C (with some exceptions for treated hepatitis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
This study tests a new oral medication called pirtobrutinib in people with previously untreated CLL or SLL. Researchers will collect blood and lymph node samples to understand how the immune system responds to the drug.
This trial tests a new pill, pirtobrutinib, for people 75 or older with chronic lymphocytic leukemia (CLL) who have never had treatment before. The goal is to see if it helps control the disease with manageable side effects.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Hear when a new Mature B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.